Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2066-2073

  Han, Minje ^a,b   Jun, Sun Hee ^a   Lee, Jae Ho ^a,b   Park, Kyoung Un ^a,b   Song, Junghan ^a,b   Song, Sang Hoon ^b,c  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Multiplex analysis; Tandem mass spectrometry; Therapeutic drug monitoring

Indexed keywords

ACETONITRILE; AMINOSALICYLIC ACID; AMMONIUM FORMATE; CLARITHROMYCIN; CYCLOSERINE; FORMIC ACID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; STREPTOMYCIN;

ARTICLE; BLOOD SAMPLING; CHROMATOGRAPHY; CONCENTRATION (PARAMETERS); DRUG EFFECT; HUMAN; IONIZATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; PILOT STUDY; TANDEM MASS SPECTROMETRY; TUBERCULOSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

MULTIPLEX ANALYSIS; TANDEM MASS SPECTROMETRY; THERAPEUTIC DRUG MONITORING;

ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; SENSITIVITY AND SPECIFICITY; SERUM; TANDEM MASS SPECTROMETRY; TIME FACTORS; TUBERCULOSIS;

EID: 84882665162     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt154     Document Type: Article

References (33)

1. WHO. 2010/2011 Tuberculosis Global Facts. http://www.who.int/entity/tb/publications/2010/factsheet_tb_2010.pdf (10 November 2011, date last accessed).
2. Kim HJ. Current situation of tuberculosis and its control in Korea. J Korean Med Assoc 2006; 49: 762-72.
3. KohWJ, Ko Y, Kim CK et al. Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. Ann Lab Med 2012; 32: 264-9.
4. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-43.
5. Koh WJ, Kang YR, Jeon K et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012; 67: 1503-7.
6. Lee M, Lee J, Carroll MW et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-18.
7. Sturdy A, Goodman A, José RJ et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011; 66: 1815-20.
8. Falzon D, Jaramillo E, Schünemann HJ et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-28.
9. Vu DH, Bolhuis MS, Koster RA et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrugresistant tuberculosis. Antimicrob Agents Chemother 2012; 56: 5758-63.
10. Alffenaar JW, Kosterink JG, van Altena R et al. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 2010; 32: 97-101.
11. Pea F, Viale P, Cojutti P et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012; 67: 2034-42.
12. Manika K, Chatzika K, Zarogoulidis K et al. Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?. Eur Respir J 2012; 40: 1051-3.
13. Pranger AD, Kosterink JG, vanAltenaRet al. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit 2011; 33: 350-4.
14. Song SH, Jun SH, Park KU et al. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 1331-8.
15. Notari S, Mancone C, Sergi M et al. Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF. IUBMB Life 2010; 62: 387-93.
16. Pranger AD, Alffenaar JW, Wessels AM et al. Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography-tandem mass spectrometry method. J Anal Toxicol 2010; 34: 135-41.
17. Meredith SA, Smith PJ, Norman J et al. An LC-MS/MS method for the determination of ofloxacin in 20 ml human plasma. J Pharm Biomed Anal 2012; 58: 177-81.
18. Vu DH, Koster RA, Alffenaar JW et al. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 1063-70.
19. Pastorini E, Locatelli M, Simoni P et al. Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 99-106.
20. Patel DS, Sharma N, Patel MC et al. Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2265-73.
21. la Marca G, Villanelli F, Malvagia S et al. Rapid and sensitive LC-MS/MS method for the analysis of antibiotic linezolid on dried blood spot. J Pharm Biomed Anal 2012; 67-68: 86-91.
22. Ji HY, Jeong DW, Kim YH et al. Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levofloxacin in human plasma. J Pharm Biomed Anal 2006; 41: 622-7.
23. Oswald S, Peters J, Venner M et al. LC-MS/MS method for the simultaneous determination of clarithromycin, rifampicin and their main metabolites in horse plasma, epithelial lining fluid and broncho-alveolar cells. J Pharm Biomed Anal 2011; 55: 194-201.
24. National Committee for Clinical Laboratory Standards. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach: Approved Guideline EP6-A. NCCLS, Wayne, PA, USA, 2003.
25. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003; 49: 1041-4.
26. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003; 75: 3019-30.
27. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.
28. Heysell SK, Moore JL, Keller SJ et al. Therapeutic drug monitoring for slow responseto tuberculosis treatmentinastate control program, Virginia, USA. Emerg Infect Dis 2010; 16: 1546-53.
29. Magis-Escurra C, van den Boogaard J, Ijdema D et al. Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther 2012; 25: 83-6.
30. Babalik A, Mannix S, Francis D et al. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J 2011; 18: 225-9.
31. Shen A, Morgan L, Barroso ML et al. Method Development of LC-MS/MS Analysis of Aminoglycoside Drugs: Challenges and Solutions. http://www.tandemlabs.com/documents/ASMS08-Angela-Web.pdf (9 November 2012, date last accessed).
32. AlffenaarJW. Dried blood spot analysis combinedwith limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs. J Infect Dis 2012; 205: 1765-6; author reply 1766.
33. Vu DH, Alffenaar JW, Edelbroek PM et al. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des 2011; 17: 2931-9.